Trials / Completed
CompletedNCT04672941
Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
Quality of Life and Preference of COPD Patients After Switching From Tiotropium Monotherapy (Spiriva® Handihaler®) to Dual Therapy With Tiotropium Bromide Plus Olodaterol (Spiolto® Respimat®) Under Real Life Conditions in Greece (ELLACTO II Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,396 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium bromide plus Olodaterol | Tiotropium bromide plus Olodaterol |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2022-02-21
- Completion
- 2022-02-21
- First posted
- 2020-12-17
- Last updated
- 2024-06-25
- Results posted
- 2023-11-28
Locations
2 sites across 1 country: Greece
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04672941. Inclusion in this directory is not an endorsement.